Kaleido Biosciences, Inc. Common Stock
KLDO
KLDO was delisted on the 14th of April, 2022.
60 hedge funds and large institutions have $213M invested in Kaleido Biosciences, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 16 increasing their positions, 12 reducing their positions, and 5 closing their positions.
300% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 5
41% more capital invested
Capital invested by funds: $151M → $213M (+$62.3M)
33% more funds holding
Funds holding: 45 → 60 (+15)
33% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 12
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FP
Flagship Pioneering
Cambridge,
Massachusetts
|
+$13.4M |
| 2 |
HP
Harbourvest Partners
Boston,
Massachusetts
|
+$4.47M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$3.35M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.94M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$1.18M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$656K |
| 3 |
Invesco
Atlanta,
Georgia
|
-$508K |
| 4 |
BlackRock
New York
|
-$172K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$106K |
KLDO Hedge Fund Activity: Q2 2020 in Review
60 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Kaleido Biosciences, Inc. Common Stock (KLDO) for Q2 2020, worth a combined $213M — up 41% from $151M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new KLDO positions and 5 closed out — a net gain of 15 holders — while 16 added to existing stakes and 12 trimmed.
The largest buyer was Flagship Pioneering, adding an estimated $13.4M. The largest seller was Victory Capital Management, cutting an estimated $1.18M.
- 60 institutional investors held Kaleido Biosciences, Inc. Common Stock (KLDO) as of Q2 2020, up from 45 in Q1 2020.
- Funds reported $213M of Kaleido Biosciences, Inc. Common Stock stock for Q2 2020, up 41% quarter-over-quarter.
- 20 funds opened new Kaleido Biosciences, Inc. Common Stock positions in Q2 2020 and 5 closed out, a net change of +15 holders.
- The largest Kaleido Biosciences, Inc. Common Stock buyer in Q2 2020 was Flagship Pioneering, an estimated $13.4M added.
- The largest Kaleido Biosciences, Inc. Common Stock seller in Q2 2020 was Victory Capital Management, an estimated $1.18M sold.
Based on aggregated 13F filings for Q2 2020.